Association of Infliximab and Vedolizumab Trough Levels with Reported Rates of Adverse Events: A Cross-Sectional Study

Infliximab and vedolizumab are effective treatments for inflammatory bowel disease (IBD), although associated with adverse events (AE). While low or non-existent drug levels and positive antidrug antibodies have been associated with therapeutic failure, there is no clear association between higher d...

Descripción completa

Detalles Bibliográficos
Autores principales: Veisman, Ido, Barzilay, Oranit, Bruckmayer, Liora, Haj-Natour, Ola, Kopylov, Uri, Eliakim, Rami, Ben-Horin, Shomron, Ungar, Bella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471987/
https://www.ncbi.nlm.nih.gov/pubmed/34575376
http://dx.doi.org/10.3390/jcm10184265

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471987/
https://www.ncbi.nlm.nih.gov/pubmed/34575376
http://dx.doi.org/10.3390/jcm10184265

Ejemplares similares